CD4 and neoplasm: A higher CD4/CD8 ratio in the tumor microenvironment was also noted in patients whose tumors had antitumor activity to afatinib/pembrolizumab, but this was not statistically significant (p = 0.4) with a small sample size (Supplementary Fig. 3).